Cécile Conte1,2,3, Flora Vayr3,4, Marie-Christelle Pajiep1,2,3, Fabien Despas1,2,3, Françoise Huguet5, Maryse Lapeyre Mestre1,2,3, Martin Gauthier6,7, Fabrice Herin3,4. 1. Clinical Pharmacology Department, Toulouse University Hospital, Toulouse, France. 2. Inserm Unit 1027, University of Toulouse 3, Toulouse, France. 3. Clinical Investigation Center (CIC 1436, INSERM and Toulouse University Hospital, Toulouse, France. 4. Occupational Diseases Department, Toulouse University Hospital, Toulouse, France. 5. Department of Haematology, Toulouse University Hospital, IUCT-O, Toulouse, France. 6. Department of Internal Medicine and Haematology, CH Cahors, Cahors, France. martin.gauthier@hotmail.fr. 7. Haematology Department, Centre Hospitalier de Cahors, 52, place Antonin Bergon, 46000, Cahors, France. martin.gauthier@hotmail.fr.
Abstract
BACKGROUND: The advent of chronic myeloid leukaemia (CML) tyrosine-kinase inhibitors (TKI) has led to new paradigms including occupational rehabilitation. OBJECTIVES: This study aimed to characterize the impact of CML treatment on sick leaves within the 2 years following diagnosis in working-age patients. METHODS: A cohort of all 18-60-year-old newly diagnosed CML patients initiating a TKI between January 1st 2011 and December 31st 2014 in France was identified in the French National Healthcare database (Système National des Données de Santé [SNDS]). Patients with a sick leave identified in the 24 months after TKI initiation were compared with sex and initiation date matched controls in a nested case-control design. Factors associated with sick leaves were identified through a conditional logistic regression model, providing adjusted odds-ratio (OR) with their 95% confidence interval (CI). RESULTS: Among 646 18-60-year-old patients, 268 were prescribed at least one sick leave in the study period, with 176 (27.2%) having their first sick leave prescribed after TKI initiation. The median number of sick days over the 2-years period was 115 per patient (interquartile range 25.5-384.5). In the nested case-control study (176 cases and 176 matched controls), sick leaves were more likely observed with second generation TKI (OR 4.11 [1.80-9.38]), whereas they were less likely observed in case if social deprivation (OR 0.07 [0.02-0.28]. CONCLUSION: More than 25% of working-age CML patients had at least one sick leave within 2 years of TKI initiation, with a higher impact of second generation TKI, and with a median duration of 115 days.
BACKGROUND: The advent of chronic myeloid leukaemia (CML) tyrosine-kinase inhibitors (TKI) has led to new paradigms including occupational rehabilitation. OBJECTIVES: This study aimed to characterize the impact of CML treatment on sick leaves within the 2 years following diagnosis in working-age patients. METHODS: A cohort of all 18-60-year-old newly diagnosed CML patients initiating a TKI between January 1st 2011 and December 31st 2014 in France was identified in the French National Healthcare database (Système National des Données de Santé [SNDS]). Patients with a sick leave identified in the 24 months after TKI initiation were compared with sex and initiation date matched controls in a nested case-control design. Factors associated with sick leaves were identified through a conditional logistic regression model, providing adjusted odds-ratio (OR) with their 95% confidence interval (CI). RESULTS: Among 646 18-60-year-old patients, 268 were prescribed at least one sick leave in the study period, with 176 (27.2%) having their first sick leave prescribed after TKI initiation. The median number of sick days over the 2-years period was 115 per patient (interquartile range 25.5-384.5). In the nested case-control study (176 cases and 176 matched controls), sick leaves were more likely observed with second generation TKI (OR 4.11 [1.80-9.38]), whereas they were less likely observed in case if social deprivation (OR 0.07 [0.02-0.28]. CONCLUSION: More than 25% of working-age CML patients had at least one sick leave within 2 years of TKI initiation, with a higher impact of second generation TKI, and with a median duration of 115 days.
Authors: Hannah Bower; Magnus Björkholm; Paul W Dickman; Martin Höglund; Paul C Lambert; Therese M-L Andersson Journal: J Clin Oncol Date: 2016-06-20 Impact factor: 44.544
Authors: Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker Journal: N Engl J Med Date: 2003-03-13 Impact factor: 91.245
Authors: Tim P Hughes; Jaspal Kaeda; Susan Branford; Zbigniew Rudzki; Andreas Hochhaus; Martee L Hensley; Insa Gathmann; Ann E Bolton; Iris C van Hoomissen; John M Goldman; Jerald P Radich Journal: N Engl J Med Date: 2003-10-09 Impact factor: 91.245
Authors: Jorge E Cortes; Giuseppe Saglio; Hagop M Kantarjian; Michele Baccarani; Jiří Mayer; Concepción Boqué; Neil P Shah; Charles Chuah; Luis Casanova; Brigid Bradley-Garelik; George Manos; Andreas Hochhaus Journal: J Clin Oncol Date: 2016-05-23 Impact factor: 44.544
Authors: Timothy P Hughes; Pierre Laneuville; Philippe Rousselot; David S Snyder; Delphine Rea; Neil P Shah; David Paar; Elisabetta Abruzzese; Andreas Hochhaus; Jeffrey H Lipton; Jorge E Cortes Journal: Haematologica Date: 2018-08-09 Impact factor: 9.941
Authors: A Hochhaus; M Baccarani; R T Silver; C Schiffer; J F Apperley; F Cervantes; R E Clark; J E Cortes; M W Deininger; F Guilhot; H Hjorth-Hansen; T P Hughes; J J W M Janssen; H M Kantarjian; D W Kim; R A Larson; J H Lipton; F X Mahon; J Mayer; F Nicolini; D Niederwieser; F Pane; J P Radich; D Rea; J Richter; G Rosti; P Rousselot; G Saglio; S Saußele; S Soverini; J L Steegmann; A Turkina; A Zaritskey; R Hehlmann Journal: Leukemia Date: 2020-03-03 Impact factor: 11.528